Universal multi-variant detection system

• US 8,192,939 B2
• Filed: 01/28/2008
• Issued: 06/05/2012
• Est. Priority Date: 04/17/2001
• Status: Expired due to Fees

• Current Assignee: New York Blood Center Incorporated
• Original Assignee: New York Blood Center Incorporated
• Inventors: Andrus, Linda, Nichols, Carmen Nicola
• Primary Examiner(s): Kim, Young J
• Application Number:
  US12/011,603
• Publication Number:
  US 20110053138A1
• Time in Patent Office: 1,590 Days
• Field of Search: None
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6818 involving interaction of two or more labels, e.g. resonant energy transfer
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: C12Q 1/702 for retroviruses
• CPC Class Codes: C12Q 1/703 Viruses associated with AIDS
• CPC Class Codes: C12Q 1/706 for hepatitis
• CPC Class Codes: C12Q 1/707 non-A, non-B Hepatitis, excluding hepatitis D
• CPC Class Codes: C12Q 2525/301 Hairpin oligonucleotides
• CPC Class Codes: C12Q 2535/125 Allele specific primer extension
• CPC Class Codes: C12Q 2537/101 Homogeneous assay format, e.g. one pot reaction
• CPC Class Codes: C12Q 2561/113 Real time assay

Abstract

The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.

Claims

1. A method for determining the presence of a viral target nucleic acid molecule in a sample containing a virus, the method comprising:

(a) hybridizing a reverse primer to the viral target nucleic acid molecule under conditions suitable for carrying out a primer extension chain reaction;

(b) extending the reverse primer using the viral target nucleic acid molecule as a template to form a reverse primer extension product, wherein the reverse primer joined to the reverse primer extension product constitutes a reverse primer amplification product;

(c) denaturing the reverse primer amplification product from its template;

(d) hybridizing a forward primer to;

(i) a nucleic acid molecule which is complementary to the viral target nucleic acid molecule, if present;

or

(ii) the reverse primer amplification product;

(e) extending the forward primer using the complementary target nucleic acid molecule, if present, or the reverse primer amplification product, as a template, wherein the forward primer joined to the forward primer extension product constitutes a forward primer amplification product;

(f) denaturing the forward primer amplification product from its template;

(g) hybridizing the reverse primer to the forward primer amplification product;

(h) extending the reverse primer using the forward primer amplification product as a template to form an additional reverse primer extension product, wherein the reverse primer joined to the additional reverse primer extension product constitutes an additional reverse primer amplification product;

(i) denaturing the additional reverse primer amplification product from its template;

(j) hybridizing the forward primer to the reverse primer amplification product;

(k) extending the forward primer using the reverse primer amplification product as a template to form an additional forward primer extension product, wherein the forward primer joined to the additional forward primer extension product constitutes an additional forward primer amplification product;

(l) denaturing the additional forward primer amplification product from its template;

(m) repeating steps (g) through (I), using the additional reverse primer amplification product and the additional forward primer amplification product as templates for the forward primer and the reverse primer, respectively, a sufficient number of times to produce a detectable quantity of additional reverse primer amplification product or of additional forward primer amplification product; and

(n) detecting the presence of the additional reverse primer amplification product or the additional forward primer amplification product;

the improvement wherein the nucleotide at the 3′

end of the reverse primer hybridizes with;

(i) the nucleotide at the 5′

end of the forward primer extension product or of the additional forward primer extension product;

or

(ii) a nucleotide separated from the nucleotide at the 5′

end of the forward primer extension product or of the additional forward primer extension product by a gap of two nucleotides, wherein the gap comprises a sequence known to be highly conserved; and

wherein the nucleotide at the 3′

end of the forward primer hybridizes with;

(i) the nucleotide at the 5′

end of the reverse primer extension product or of the additional reverse primer extension product;

or

(ii) a nucleotide separated from the nucleotide at the 5′

end of the reverse primer extension product or of the additional reverse primer extension product by a gap of two nucleotides, wherein the gap comprises a sequence known to be highly conserved.

2. The method according to claim 1 wherein the primer extension chain reaction is a polymerase chain reaction (PCR).

3. The method according to claim 1 wherein the virus is a human immunodeficiency virus (HIV).

4. The method according to claim 1 wherein the virus is a hepatitis C virus (HCV) or a hepatitis B virus (HBV).

5. The method according to claim 1 wherein the gap comprises a highly conserved region of the genome of the virus.

6. The method according to claim 1 wherein the nucleic acid molecule which is complementary to the viral target nucleic acid molecule of step (d)(i) is provided separately as the cDNA of the viral target nucleic acid molecule.

7. The method of claim 1, wherein the viral target nucleic acid molecule is known to have variant sequences, and wherein said method is performed using a kit comprising:

(i) a set of nose-to-nose primers comprising a forward primer and a reverse primer;

(ii) reagents for performing a primer extension chain reaction and;

(iii) a self-altering signal-generating probe which detects the presence of primer amplification products, wherein the probe comprises a first nucleic acid sequence attached to a reporter moiety capable of generating a detectable signal;

a second nucleic acid sequence attached to an interactive moiety capable of altering the signal of the reporter moiety; and

a probe sequence which connects the first and second nucleic acid sequences.

8. The method according to claim 7 wherein the second nucleic acid sequence of the self-altering signal-generating probe is hybridized to the first nucleic acid sequence of the self-altering signal-generating probe and wherein the probe sequence comprises either:

(a) the nucleotide sequence of a segment of the forward primer;

or

(b) the nucleotide sequence of a segment of the reverse primer; and

wherein upon contacting the amplification products with the probe, the probe sequence of the probe hybridizes with the additional reverse primer amplification product or with the additional forward primer amplification product, and the first and second nucleic acid sequences become denatured, thereby generating a detectable signal by the reporter moiety; and

wherein the detectable signal generated by the reporter moiety indicates the presence of the target molecule.

9. The method according to claim 8 wherein the probe sequence comprises either:

(a) the nucleotide sequence of a segment of the forward primer, and not the nucleotide sequence of a segment which is complementary to the reverse primer;

or

(b) the nucleotide sequence of a segment of the reverse primer, and not the nucleotide sequence of a segment which is complementary to the forward primer.

10. The method according to claim 8 wherein the probe sequence comprises either:

(a) the nucleotide sequence of a segment of the forward primer and the nucleotide sequence of a segment which is complementary to the reverse primer;

or

(b) the nucleotide sequence of a segment of the reverse primer and the nucleotide sequence of a segment which is complementary to the forward primer.

11. The method according to claim 10 wherein about sixty to about ninety-five percent of the probe sequence comprises either:

(i) the nucleotide sequence of a segment of the forward primer;

or

(ii) the nucleotide sequence of a segment of the reverse primer.

12. The method according to claim 8 wherein the level of the detectable signal generated by the probe is proportional to the quantity of the target nucleic acid molecule in the sample.

13. The method according to claim 8 wherein:

if the probe sequence comprises the nucleotide sequence of a segment of the reverse primer, the molar ratio of the reverse primer to the forward primer is in the range from about 1;

5 to about 1;

20;

or

if the probe sequence comprises the nucleotide sequence of a segment of the forward primer, the molar ratio of the forward primer to the reverse primer is in the range from about 1;

5 to about 1;

20.

14. The method according to claim 8 wherein the probe sequence comprises from about ten to about thirty nucleotide residues.

15. The method according to claim 14 wherein the probe sequence comprises from about eighteen to about twenty-four nucleotide residues.

16. The method according to claim 8 wherein the detectable signal is a luminescent signal.

17. The method according to claim 16 wherein the luminescent signal is a fluorescent signal.

18. The method according to claim 16 wherein the luminescent signal is chemiluminescent signal.

19. The method of claim 8 wherein the reporter moiety is attached at the 5′

terminus or 3′

terminus of the self-altering signal-generating probe.

20. The method of claim 8 wherein the interactive moiety is attached at the 5′

terminus or 3′

terminus of the self-altering signal-generating probe.

21. The method according to claim 8 wherein the reporter moiety is a fluorophore.

22. The method according to claim 21 wherein the fluorophore is a xanthene dye, a cyanine dye, a dansyl derivative, EDANS, coumarin, Lucifer yellow, BODIPY, Cy3, Cy5, Cy7, Texas red, erythrosine, naphthylamine, Oregon green, or combinations thereof.

23. The method according to claim 22 wherein the xanthene dye is a fluorescein or a rhodamine.

24. The method according to claim 23 wherein the fluorescein is selected from the group consisting of 5-carboxyfluorescein (5-FAM);

6-carboxyfluorescein (6-FAM);

2′

,4′

,1,4,-tetrachlorofluorescein (TET);

2′

,4′

,5′

,7′

, 1,4-hexachlorofluorescein (HEX);

eosin;

calcium green; and

NED.

25. The method according to claim 23 wherein the rhodamine is selected from the group consisting of tetramethyl-6-carboxyrhodamine (TAMRA);

tetrapropano-6-carboxyrhodamine (ROX);

2′

,7′

dimethoxy-4′

,5′

-dichloro-6-carboxyrhodamine (JOE); and

tetramethylrhodamine.

26. The method according to claim 8 wherein the interactive moiety is a quencher.

27. The method according to claim 26 wherein the quencher is DABCYL, anthroquinone, nitrothiazole, nitroimidazole or malachite green.

28. The method according to claim 27 wherein the DABCYL is DABSYL, DABMI or methyl red.

29. The method according to claim 8 wherein the interactive moiety is a fluorophore.

30. The method of claim 7 wherein the amplification products are measured and quantitated by end-point analysis.

31. The method of claim 7 wherein the amplification products are measured and quantitated by real-time analysis.

32. The method of claim 7 wherein the amplification products are measured using a standard curve derived from a series of threshold cycle measurements.